Home
PODD

PODD

Insulet Corporation

as of 03-05-2026 12:19pm EST

$240.01

$2.88

-1.19%

Stocks Health Care Medical/Dental Instruments Nasdaq

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.

Chart Type:

Time Range:

Founded:	2000	Country:	United States
Employees:	N/A	City:	ACTON
Market Cap:	17.0B	IPO Year:	2007
Target Price:	$358.00	AVG Volume (30 days):	1.0M
Analyst Decision:	Strong Buy	Number of Analysts:	20
Dividend Yield:	N/A	Dividend Payout Frequency:	N/A
EPS:	3.48	EPS Growth:	-39.79
52 Week Low/High:	$230.08 - $354.88	Next Earning Date:	05-20-2026
Revenue:	$2,708,100,000	Revenue Growth:	30.73%
Revenue Growth (this year):	24.33%	Revenue Growth (next year):	19.33%
P/E Ratio:	70.10	Index:	SP500
Free Cash Flow:	377.7M	FCF Growth:	+23.71%

AI-Powered PODD Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 18 hours ago

AI Recommendation

hold

Model Accuracy: 72.50%

72.50%

Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

View Full PODD Forecast & Prediction with Hourly Data

Stock Insider Trading Activity of Insulet Corporation (PODD)

MINOGUE MICHAEL R

Director

Buy

PODD Feb 25, 2026

Avg Cost/Share

$246.23

2,030

Total Value

$499,846.90

Owned After

17,483

SEC Form 4

Form 1

McEvoy Ashley

President and CEO

Buy

PODD Feb 20, 2026

Avg Cost/Share

$239.35

4,300

Total Value

$1,029,205.00

Owned After

13,916

SEC Form 4

Form 1

Frederick Wayne A.I.

Director

Sell

PODD Dec 15, 2025

Avg Cost/Share

$293.09

1,851

Total Value

$542,509.59

Owned After

2,158

SEC Form 4

Form 1

STONESIFER TIMOTHY C.

Director

Buy

PODD Dec 5, 2025

Avg Cost/Share

$311.73

962

Total Value

$299,884.26

Owned After

4,591

SEC Form 4

Form 1

Insider	Ticker	Relationship	Date	Transaction	Avg Cost	Shares	Total Value	Owned After	SEC Forms
MINOGUE MICHAEL R	PODD	Director	Feb 25, 2026	Buy	$246.23	2,030	$499,846.90	17,483	Form
McEvoy Ashley	PODD	President and CEO	Feb 20, 2026	Buy	$239.35	4,300	$1,029,205.00	13,916	Form
Frederick Wayne A.I.	PODD	Director	Dec 15, 2025	Sell	$293.09	1,851	$542,509.59	2,158	Form
STONESIFER TIMOTHY C.	PODD	Director	Dec 5, 2025	Buy	$311.73	962	$299,884.26	4,591	Form

Earnings Transcripts

SEC 8-K filings with transcript text

View All

2025

Q4 2025 Earnings

8-K SELL

Feb 18, 2026 · 100% conf.

SEC

View on SEC.gov

AI Prediction SELL

-1.32%

$254.65

-4.42%

$246.65

20D

-0.57%

$256.61

Price: $258.07 Prob +5D: 0% AUC: 1.000

0001145197-26-000026

podd-202602180001145197FALSE00011451972026-02-182026-02-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 18, 2026

INSULET CORPORATION

(Exact Name of Registrant as Specified in Charter)

Delaware001-3346204-3523891 (State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)

100 Nagog Park ActonMassachusetts01720 (Address of Principal Executive Offices, including Zip Code)

Registrant’s telephone number, including area code: (978)600-7000

Not Applicable (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided pursuant to Section 13(a) of the Exchange Act☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.001 Par Value Per Share PODDThe NASDAQ Stock Market, LLC

Item 2.02.Results of Operations and Financial Condition.

On February 18, 2026, Insulet Corporation (the “Company”) announced its financial results for the fourth quarter and year ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 7.01.Regulation FD Disclosure

On February 13, 2026, the Board of Directors of Insulet Corporation (the “Company”) approved a $350 million increase in the previously authorized $125 million stock repurchase authorization and extended the authorization through December 31, 2027. With this additional authorization, the total authorization for the repurchase program allows for the purchase of up to $475 million in shares of the Company’s common stock. As of February 16, 2026, the Company has repurchased $60 million in shares under the repurchase program, leaving $415 million in shares available under the repurchase program. The Company expects to continue to fund repurchases with existing cash and plans to allocate approximately $300 million toward repurchases in the first quarter of 2026. The Company has no obligation to repurchase shares, and the share repurchase program may be extended, modified, suspended or discontinued by the Company at any time.

Item 9.01.Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No.Description

99.1 Press Release dated February 18, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned thereunto duly authorized.

INSULET CORPORATION

February 18, 2026 By: /s/ Flavia H. Pease Flavia H. Pease Chief Financial Officer, Executive Vice President (Principal Financial Officer)

2025

Q3 2025 Earnings

8-K

Nov 6, 2025

SEC

View on SEC.gov

0001145197-25-000067

podd-202511060001145197FALSE00011451972025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 6, 2025